Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | LADIE study: NSCLC in women

Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, highlights data published on the IFCT-1003 LADIE study. This phase II randomized study evaluated the treatment of patients with EGFR-TKI alongside fulvestrant, an anti-estrogen therapy, in women with non-squamous advanced stage non-small cell lung cancer. The study concluded that adding fulvestrant to EGFR-TKI is feasible, but not associated with prolonged PFS regardless EGFR status. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).